The Technical Analyst
Sierra Oncology Inc [SRRA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Sierra Oncology Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $54.99
America/New_York / 31 des 1970 @ 19:00
| RATING 2022-07-01 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -8.34 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.42x |
| Company: PE -8.34 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 54.67 - 55.31 ( +/- 0.59%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-07-01 | Vivo Opportunity, Llc | Sell | 431 947 | Common Stock |
| 2022-07-01 | Vivo Opportunity, Llc | Sell | 75 749 | Series A Warrants |
| 2022-07-01 | Orbimed Advisors Llc | Sell | 226 704 | Common Stock |
| 2022-07-01 | Orbimed Advisors Llc | Sell | 170 437 | Series A Warrants |
| 2022-07-01 | Ashiya Mona | Sell | 226 704 | Common Stock |
| INSIDER POWER |
|---|
| -97.14 |
| Last 99 transactions |
| Buy: 4 604 902 | Sell: 10 646 034 |
Forecast:
01:40 - $61.42
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $54.99 (0.00% ) |
| Volume | 0 mill |
| Avg. Vol. | 0.651 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SRRA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SRRA
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.
Last 10 Buy Signals
Latest Press Releases
2022-05-05 14:59:00 - Press Release
Sierra Oncology Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Sierra Oncology, Inc - Srra
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of sierra oncology, inc (nasdaqgm: srra) to glaxosmithkline plc (nyse: gsk). under the terms of the proposed transaction, shareholders of sierra will receive only $55.00 in cash for each share of sierra that they own. ksf is seeking to determine whether this consideration and the process that led to it are adequa
2022-05-02 16:57:00 - Press Release
Sierra Oncology Investor Alert - Kuznicki Law Pllc Investigates Proposed Sale Of Sierra Oncology, Inc - Srra
Cedarhurst, n.y.--(business wire)--kuznicki law pllc is investigating the proposed sale of sierra oncology, inc (nasdaqgm: srra) to glaxosmithkline plc (nyse: gsk). under the terms of the proposed transaction, shareholders of sierra will receive only $55.00 in cash for each share of sierra that they own. if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, contact us toll free at 833-938-0905, via email (dk@kclasslaw.com), or vi
2022-04-13 15:15:00 - Press Release
Shareholder Alert: Weiss Law Investigates Sierra Oncology, Inc.
New york , april 13, 2022 /prnewswire/ -- weiss law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of sierra oncology, inc. ("sierra" or the "company") (nasdaq: srra), in connection with the proposed acquisition of the company by glaxosmithkline plc (nyse: gsk). under the terms of the merger agreement, the company's shareholders will receive $55.00 in cash for each share of sierra common stock owned.
2022-04-13 02:05:00 - Press Release
Gsk Reaches Agreement To Acquire Late-stage Biopharmaceutical Company Sierra Oncology For $1.9bn
London--(business wire)--glaxosmithkline plc (lse/nyse: gsk) and sierra oncology, inc (nasdaq: srra) today announced that the companies have entered into an agreement under which gsk will acquire sierra oncology, a california-based, late-stage biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer, for $55 per share of common stock in cash representing an approximate total equity value of $1.9 billion (£1.5 billion). myelofibrosis is a fatal cancer of
2022-01-27 07:00:00 - Press Release
Sierra Oncology To Present At B. Riley Securities Oncology Investor Conference
San mateo, calif.--(business wire)--sierra oncology, inc. (nasdaq: srra), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 2022 b. riley securities oncology investor conference being held virtually from january 27-28, 2022. president and chief executive officer stephen dilly, mbbs, phd, will provide an overview of the company at 2:30 pm et on friday, january 28, 2022. a replay of the presentat
Latest News
2022-06-02 10:33:08 - Zacks Investment Research
GSK Receives Regulatory Nod for Consumer Healthcare Demerger
GSK progresses with the separation of its Consumer Healthcare business from biopharmaceuticals into a separate public company, Haleon, as it gets regulatory approval from the FCA.
2022-04-14 13:50:44 - Stockmarketcom
Best Biotech Stocks To Buy Now? 5 To Know
2022-04-13 13:49:54 - Invezz
Late-Stage Biopharmaceutical Sierra Oncology announces acquisition by GSK
Sierra Oncology (NASDAQ: SRRA) shares traded significantly higher after announcing the acquisition by GlaxoSmithKline PLC (LON: GSK) for $55 a share in cash. That represents a total equity value of $1.9 billion, attributed mainly to SRRA's Momelotinib, a differentiated mode of action with inhibitory activity and critical signalling pathways.
2022-04-13 11:42:38 - InvestorPlace
Why Is Sierra Oncology (SRRA) Stock Up Today?
Late-phase cancer treatment company Sierra Oncology is up big today after being acquired by GlaxoSmithKline. SRRA stock is soaring.
2022-04-13 11:20:09 - Benzinga
Sierra Oncology Stock Is Soaring: Here's Why
Sierra Oncology Inc (NASDAQ: SRRA) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKline PLC (NYSE: GSK) for $55 per share in cash, representing an approximate total equity value of $1.9 billion. GSK believes Sierra.
2022-04-13 10:10:28 - Schaeffers Research
Sierra Oncology Stock Soars After Buyout
Sierra Oncology Inc (NASDAQ:SRRA) stock is soaring today, up 38% at $54.52, after news that GlaxoSmithKline (GSK) is purchasing the company for $1.9 billion.
2022-04-13 08:32:24 - Market Watch
GSK to buy Sierra Oncology for $1.9 billion
Shares of Sierra Oncology Inc. SRRA, +3.10% soared 37.3% in premarket trading on Wednesday after GlaxoSmithKline GSK, +0.11% GSK, +0.63% said it would buy the company for $1.9 billion. Sierra is developing treatments for rare types of cancer, including myelofibrosis, and announced in January that momelotinib met the primary and secondary endpoints in a Phase 3 clinical trial evaluating the experimental therapy as a treatment for myelofibrosis.
2022-04-13 08:19:00 - Barrons
Sierra Oncology Soars After Takeover by Glaxo
The deal comes ahead of GlaxoSmithKline's planned spinoff of its consumer health division in July.
2022-04-13 08:14:41 - The Motley Fool
Why Sierra Oncology Stock Is Soaring Today
GlaxoSmithKline is adding another cancer asset to its portfolio by acquiring U.S.-based Sierra Oncology.
2022-04-13 08:08:02 - Benzinga
GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal
GlaxoSmithKline plc (NYSE: GSK) has agreed to acquire Sierra Oncology Inc (NASDAQ: SRRA) for $55 per share in cash, representing an approximate total equity value of $1.9 billion (£1.5 billion). Sierra's momelotinib complements GSK's Blenrep (belantamab.